Androgen receptor-positive triple negative breast cancer: A unique breast cancer subtype

Annals of Surgical Oncology

Volumn 21, Issue 2, 2014, Pages 361-367

  McGhan, Lee J ^a   McCullough, Ann E ^a   Protheroe, Cheryl A ^b   Dueck, Amylou C ^a   Lee, James J ^b   Nunez Nateras, Rafael ^a   Castle, Erik P ^a   Gray, Richard J ^a   Wasif, Nabil ^a   Goetz, Matthew P ^c   Hawse, John R ^d   Henry, Travis J ^b   Barrett, Michael T ^e   Cunliffe, Heather E ^e   Pockaj, Barbara A ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic Collaborative Research Building ^*  (United States)

^c MAYO CLINIC   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

^e TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR;

ADULT; ADVANCED CANCER; AGE; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LOCAL RECURRENCE FREE SURVIVAL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION;

BREAST; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ANDROGEN; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896702428     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3260-7     Document Type: Article

References (27)

1. Tiefenbacher K, Daxenbichler G. The role of androgens in normal and malignant breast tissue. Breast Care (Basel). 2008;3:325-31.
2. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1999;130(Pt 1):270-7.
3. Luo X, Shi YX, Li ZM, Jiang WQ. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer. 2010;29:585-90.
4. Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor. Cancer J. 2010;16:62-5.
5. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938-48.
6. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010;23:205-12.
7. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007 109(1):25-32.
8. He J, Peng R, Yuan Z, et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012;29:406-10.
9. Park S, Koo J, Park HS, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;21:488-92.
10. Hu R, Dawood S, Holmes MD, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011;17:1867-74.
11. Ogawa Y, Hai E, Matsumoto K, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol. 2008;13:431-5.
12. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-67.
13. Burger HG. Androgen production in women. Fertil Steril. 2002;77:S3-5.
14. Veronesi U, Pizzocaro G. Breast cancer in women subsequent to cystic disease of the breast. Surg Gynecol Obstet. 1968;126:529-32.
15. Wong YC, Xie B. The role of androgens in mammary carcinogenesis. Ital J Anat Embryol. 2001;106(Suppl 1):111-25.
16. Hackenberg R, Schulz KD. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. Steroid Biochem Mol Biol. 1996;56-6:113-7.
17. Danforth KN, Eliassen AH, Tworoger SS, et al. The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women. Int J Cancer. 2010;126:199-207.
18. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14:8010-18.
19. Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopathology. 2008;52:108-18.
20. Kanga SP, Martelb M, Harris LN. Triple negative breast cancer: current understanding of biology. Curr Opin Obstet Gynecol. 2008;20:40-6.
21. Podoa F, Buydensb LMC, Deganic H, et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol. 2010;4:2099-29.
22. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ. Androgen receptors in breast cancer. Cancer. 1984;54:2436-40.
23. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15:2472-8.
24. Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, Gilks CB. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002;117:723-8.
25. Park S, Koo JS, Kim MS, et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol. 2011;22:1755-62.
26. Billar JA, Dueck AC, Stucky CH, et al. Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol. 2010;17(Suppl. 3):384-90.
27. Collins LC, Cole KS, Marotti JD, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol. 2011;24:924-31.